Synthetic HLA-independent T cell receptors for cancer immunotherapy

Sylvain Simon; Grace Bugos; Stanley R Riddell

doi:10.1016/j.ccell.2022.03.009

Synthetic HLA-independent T cell receptors for cancer immunotherapy

Cancer Cell. 2022 Apr 11;40(4):359-361. doi: 10.1016/j.ccell.2022.03.009.

Authors

Sylvain Simon¹, Grace Bugos², Stanley R Riddell³

Affiliations

¹ Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA.
² Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA; Department of Immunology, University of Washington, Seattle, WA 98109, USA.
³ Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA; Department of Immunology, University of Washington, Seattle, WA 98109, USA; Department of Medicine, University of Washington, Seattle, WA 98109, USA. Electronic address: sriddell@fredhutch.org.

PMID: 35413270
DOI: 10.1016/j.ccell.2022.03.009

Abstract

CAR T cells are remarkably effective in hematologic malignancies, but tumor cells expressing low antigen levels can escape elimination. In Nature Medicine, Mansilla-Soto et al. design new chimeric receptors that link the variable regions of antibodies directly to T cell receptor chains and recognize tumor cells with improved antigen sensitivity.

MeSH terms

Antibodies
Humans
Immunotherapy
Immunotherapy, Adoptive*
Neoplasms* / genetics
Neoplasms* / therapy
Receptors, Antigen, T-Cell / genetics

Substances

Antibodies
Receptors, Antigen, T-Cell